| Literature DB >> 28778184 |
Yan-Bing Wu1, Li-Li Xu1, Xiao-Juan Wang1, Zhen Wang1, Jun Zhang1, Zhao-Hui Tong1, Huan-Zhong Shi2.
Abstract
BACKGROUND: Medical thoracoscopy has been shown to be an efficacious procedure in diagnosing unexplained exudative pleural effusions with excellent safety. This study aimed to assess the diagnostic significance of thoracoscopy in the management of patients with malignant pleural effusion (MPE).Entities:
Keywords: Diagnosis; Malignant pleural effusion; Pleural biopsy; Sensitivity and specificity; Thoracoscopy
Mesh:
Year: 2017 PMID: 28778184 PMCID: PMC5544982 DOI: 10.1186/s12890-017-0451-1
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Characteristics of the study population (n = 342)
| Variables | Values |
|---|---|
| Age, yr., mean ± SD | 62.8 ± 9.7 |
| Sex, male/female, n (%) | 183/159 (53.5/46.5) |
| Smoking status, n (%) | |
| Current or previous smoker | 127 (37.1) |
| Non-smoker | 149 (43.6) |
| Not clear | 66 (19.3) |
| History of malignancy | 32 (9.4) |
| CT imaging | |
| Mediastinal and hilum lymphadenopathy | 196 (57.3) |
| Pleural thickening | 159 (46.5) |
| Pulmonary consolidation or infiltration | 158 (46.2) |
| Pulmonary mass or nodules | 134 (39.2) |
| Pulmonary atelectasis | 126 (36.8) |
| Pleural nodularity | 51 (14.9) |
| Side of effusion, n (%) | |
| Right | 149 (43.6) |
| Left | 133 (38.9) |
| Bilateral | 60 (17.5) |
| Size of effusion, n (%) | |
| Small | 57 (16.7) |
| Moderate | 44 (12.9) |
| Large | 241 (70.4) |
| Effusion appearance, n (%) | |
| Blood- tinged | 191 (55.9) |
| Yellow | 151 (44.1) |
Procedural details (n = 342)
| Procedural details | Value |
|---|---|
| Pleural fluid removed, mL | 1306.7 ± 753.0 |
| Parietal pleura biopsies, n | 10 ± 2 |
| Thoracoscopic findings, n (%) | |
| Pleural nodules | 243 (71.1) |
| Hyperemia | 159 (46.5) |
| Pleural adhesion | 125 (36.6) |
| Pleural plaques | 69 (20.2) |
| Ulcer | 10 (2.9) |
| Other pleural pathological changes | 97 (28.4) |
Diagnoses established by thoracoscopy in patients with MPE (n = 342)
| Diagnoses | n (%) |
|---|---|
| Non-small cell lung cancer | 221 (64.6) |
| Adenocarcinoma | 215 (97.3) |
| Squamous cell carcinoma | 6 (2.7) |
| Small cell lung cancer | 11 (3.2) |
| Other metastatic carcinoma | 40 (11.7) |
| Malignant mesothelioma | 35 (10.2) |
| Epithelioid | |
| Sarcomatoid | |
| Biphasic | |
| Undifferentiated | |
| Lymphoma | 10 (2.9) |
| Undetermined | 25 (7.3) |
Types of metastatic cancers (n = 272)
| Metastatic cancers | n (%) |
|---|---|
| Lung cancer | 232 (85.2) |
| Breast cancer | 12 (4.4) |
| Ovarian cancer | 6 (2.2) |
| Pancreatic cancer | 5 (1.8) |
| Hepatic carcinoma | 3 (1.1) |
| Esophageal carcinoma | 2 (0.7) |
| Renal carcinoma | 2 (0.7) |
| Thymic carcinoma | 2 (0.7) |
| Gastric carcinoma | 1 (0.4) |
| Myeloma | 1 (0.4) |
| Sinuethmoid cancer | 1 (0.4) |
| Malignant hemangioendothelioma | 1 (0.4) |
| Base tongue carcinoma | 1 (0.4) |
| Malignant melanoma | 1 (0.4) |
| Cervical cancer | 1 (0.4) |
| Endometrial cancer | 1 (0.4) |